University of Leeds and IAG partred to bring a Digital Artery Volume Index (DAVIX) into Trials for Systemic Sclerosis.
IAG and Ferring Pharmaceuticals joined forces to advance Women’s Reproductive Health through AI-driven medical image analysis.
Early Asset Acquisition
35% Trial Budget Reduction
Significance Efficacy in a Rare Disease Trial Faster
Objective Go / No Go Decisions
Optimizing Patient Stratification
Value of Your Data
The partners will apply Advanced Imaging Analytics to Support Understnding of Drug Efficacy in Psoriatic Arthritis.
Licencing Deal after Phase IIa Results Announced
Confirming MoA through Advanced Imaging Endpoints
Applying AI and Advanced Imaging strategies to assess efficacy in recurrent Glioblastoma patients.
Collaboration to Deploy Artificial Intelligence Imaging Methodologies for Reliable Early Efficacy Readouts
Collaboration to Accelerate Development of Novel Breakthrough Therapies for Patients with Inflammatory Bowel Disease
Collaboration in development of a combination therapy in Metastatic Melanoma
Partnership to Advance Clinical Development of DPX-Survivac in the Treatment of Solid Tumors
Partnership to Validate Predictive Imaging Markers for Treatment Response in Solid Tumors.
Partnership to Augment Clinical Decision Making with AI Driven Methodology for Ulcerative Colitis Histopathological Image Analysis
Partnership to Develop Multi-Omics-Based Machine Learning Models to Study Glioblastoma Multiforme
Partnership to Maximize Chances of Success for Immuno-Oncology Companies through the use of Advanced Imaging Strategies.
Partnership to Objectively Assess Patient Response to a Novel Cell-Based Therapy in a Rare Paediatric Orthopaedic Condition.
The partners will apply IAG’s AI-Driven Imaging Strategy and Advanced Imaging Analytics to Support Knee Osteoarthritis Clinical Trial Program.
Partnership to Advance Connectivity and Interoperability in Clinical Trials of Rheumatic Diseases
Partnership with CNS Pharmaceuticals Partner to Further the Development of Berubicin
Partnership with WPD to Bring Novel GBM Treatments to Patients
Genenta Imaging Partnership with IAG Optimizes Phase I/IIa Study of Temferon™ in Glioblastoma.
Crescendo and IAG partner to support the clinical development of CB307 with advanced imaging analysis technology
Novel Imaging Markers in the Development of AR-67 for Patients with Recurrent Glioblastoma
Bringing new technologies into development of novel, targeted T-cell enhancing immuno-oncology therapeutics.
Confirming MoA through Advanced Imaging and AI.
The partners will apply IAG’s AI-Driven biomarkers to assess drug efficacy in early study.
The partners will apply IAG’s AI-Driven biomarkers to assess drug efficacy in Ulcerative Colitis.
